Inmune Bio Stock Investor Sentiment

INMB Stock  USD 8.17  0.22  2.77%   
About 63% of all INmune Bio's investors are looking to take a long position. The analysis of the overall investor sentiment regarding INmune Bio suggests that some traders are interested. The current market sentiment, together with INmune Bio's historical and current headlines, can help investors time the market. In addition, many technical investors use INmune Bio stock news signals to limit their universe of possible portfolio assets.
  

INmune Bio Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards INmune Bio can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
48.6%
53.9%
47.7%
52.6%
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

INmune Bio Maximum Pain Price Across April 17th 2025 Option Contracts

INmune Bio's options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of INmune Bio close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of INmune Bio's options.
Calls PricePuts Price
over six months ago at investing.com         
Earnings call INmune Bio reports on trials and financials for Q4 2023
Investing News at Macroaxis
over six months ago at simplywall.st         
INmune Bio Full Year 2023 Earnings Revenues Beat Expectations, EPS Lags
Simply Wall St News at Macroaxis
over six months ago at finance.yahoo.com         
INmune Bio Full Year 2023 Earnings Revenues Beat Expectations, EPS Lags
Yahoo News
over six months ago at gurufocus.com         
INmune Bio Inc Posts Year-End Earnings, Reveals Net Loss Amidst Clinical Advancements
Gurufocus Stories at Macroaxis
over six months ago at investorplace.com         
INMB Stock Earnings INmune Bio Misses EPS, Misses Revenue for Q4 2023
sbwire news
over six months ago at globenewswire.com         
INmune Bio Inc. Announces Year End 2023 Results and Provides a Q4 Business Update
Macroaxis News: globenewswire.com
over six months ago at finance.yahoo.com         
INmune Bio Inc. to Report Fourth Quarter 2023 Financial Results and Provide a Corporate Update on Th...
Yahoo News
over six months ago at news.google.com         
INmune Bio Shares Down 4 percent - Defense World
Google News at Macroaxis
over six months ago at simplywall.st         
Individual investors invested in INmune Bio, Inc. up 10 percent last week, insiders too were rewarde...
Simply Wall St News at Macroaxis
over six months ago at finance.yahoo.com         
INmune Bio CSO and Co-Founder Mark Lowdell, Ph.D. Receives The ISCT Career Achievement Award in Cell...
Yahoo News
over a year ago at investing.com         
INmune Bio reports EEG improvement in Alzheimers therapy
Investing News at Macroaxis
over a year ago at globenewswire.com         
INmune Bio Reports Significant EEG Improvement in Alzheimers Patients Treated with XPro
Macroaxis News: globenewswire.com
over a year ago at news.google.com         
Deutsche Bank AG Has 744000 Stock Position in INmune Bio, Inc. - Defense World
Google News at Macroaxis
over a year ago at news.google.com         
INmune Bio Set to Announce Earnings on Thursday - MarketBeat
Google News at Macroaxis
over a year ago at news.google.com         
Objective longshort Report - Stock Traders Daily.com
Google News at Macroaxis
Far too much social signal, news, headlines, and media speculation about INmune Bio that are available to investors today. That information is available publicly through INmune media outlets and privately through word of mouth or via INmune internal channels. However, regardless of the origin, that massive amount of INmune data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of INmune Bio news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of INmune Bio relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to INmune Bio's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive INmune Bio alpha.

INmune Bio Performance against Dow Jones

 Price Growth (%)  
JavaScript chart by amCharts 3.21.15123456789101112Dec2025Feb -20020406080100
JavaScript chart by amCharts 3.21.15INmune Bio INmune Bio Dividend Benchmark Dow Jones Industrial
       Timeline  
1
Acquisition by Allen Marcia of 32500 shares of INmune Bio at 5.05 subject to Rule 16b-3
12/20/2024
2
Acquisition by Lowdell Mark William of 14423 shares of INmune Bio at 8.32 subject to Rule 16b-3
12/31/2024
3
Acquisition by Moss David J of 160000 shares of INmune Bio at 9.92 subject to Rule 16b-3
01/24/2025
4
INmune Bio Rating Increased to Strong-Buy at RODMANRENSHAW - MarketBeat
01/29/2025
5
Acquisition by Xencor Inc of 192533 shares of INmune Bio at 17.14 subject to Rule 16b-3
01/30/2025
6
Acquisition by Schroeder Timothy J of 12500 shares of INmune Bio at 9.92 subject to Rule 16b-3
01/31/2025
7
Why INmune Bio Inc Is Skyrocketing So Far In 2025 - Yahoo Finance
02/03/2025
8
Why INmune Bio Inc Is Skyrocketing So Far In 2025
02/04/2025
9
INmune Bio Announces Plan to Submit FDA Biologics License Application Seeking Approval of CORDStrom for Treatment of Recessive Dystrophic Epidermolysis Bullosa
02/10/2025
10
INmune Bio Opens Phase II in High Dose Cohort of INKmune Trial in Prostate Cancer
02/12/2025
11
Acquisition by Baracchini Edgardo Jr of 35000 shares of INmune Bio subject to Rule 16b-3
03/05/2025
12
Acquisition by Lowdell Mark William of 140000 shares of INmune Bio at 5.05 subject to Rule 16b-3
03/07/2025

Complementary Tools for INmune Stock analysis

When running INmune Bio's price analysis, check to measure INmune Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy INmune Bio is operating at the current time. Most of INmune Bio's value examination focuses on studying past and present price action to predict the probability of INmune Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move INmune Bio's price. Additionally, you may evaluate how the addition of INmune Bio to your portfolios can decrease your overall portfolio volatility.
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk